Piramal Pharma Solutions (PPS) is set to invest $55m across its production sites in North America and Asia in order to expand its active pharmaceutical ingredients (API) manufacturing capabilities and capacities.

PPS, a subsidiary of Piramal Enterprises (PEL), is a major contract development and manufacturing organisation (CDMO).

The company will use a part of its investment for the development of its new and advanced multi-purpose plants with more than 270kl total capacity.

The facilities will help support PPS’s current pipeline of nearly 80 late-stage programmes designed by the company to assist its partners at several sites worldwide.

The investment will also be used to expand the firm’s potency footprint at its production plant in Riverview, Michigan, US.

“With these investments, we can now support the commercialisation of our pipeline of over 80 programmes that are at Phase II or beyond, while allowing us additional capacity for future partnerships.”

PPS CEO Vivek Sharma said: “We are committed towards investing in our customers’ future needs. With these investments, we can now support the commercialisation of our pipeline of over 80 programmes that are at Phase II or beyond, while allowing us additional capacity for future partnerships.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, PPS aims to increase its early development capabilities out of Ennore, India, through the development of good manufacturing practices (GMP) kilo labs and a pilot plant.

The company will add early development capabilities in both drug substance and drug product out of its Morpeth, UK, facility in order to provide better service to its European biotech customers.

Support functions such as analytical capabilities, research and development infrastructure, automation, and IT systems will also be expanded by the company.

Piramal supports API development and production through an integrated model across its five manufacturing sites in North America, Europe and Asia.